

side

result set

*DB=PGPB,USPT,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ*

<u>L5</u>	(chimeric or chimaeric)same(tnf\$)same(cd40L or cd154 or cd40 adj ligand or 5c8 or gp39)	101	<u>L5</u>
<u>L4</u>	(L1 or L2 or L3) and (chimeric or chimaeric)same(tnf\$)same(cd40L or cd154 or cd40 adj ligand or 5c8 or gp39)	2	<u>L4</u>
<u>L3</u>	cantwell.in.	360	<u>L3</u>
<u>L2</u>	kipps.in.	588	<u>L2</u>
<u>L1</u>	prussak.in.	30	<u>L1</u>

END OF SEARCH HISTORY

## Refine Search

### Search Results -

Term	Documents
CHIMERIC	57358
CHIMERICS	376
CHIMAERIC	1980
CHIMAERICS	4
CD40L	2481
CD40LS	4
CD154	1119
CD154S	6
CD40	6168
CD40S	0
LIGAND	136472
((CHIMERIC OR CHIMAERIC)SAME(TNFS)SAME(CD40L OR CD154 OR CD40 ADJ LIGAND OR 5C8 OR GP39)).PGPB,USPT,EPAB,JPAB,DWPI.	101

There are more results than shown above. [Click here to view the entire set.](#)

Database: 

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

[Refine Search](#)

[Recall Text](#)

[Clear](#)

[Interrupt](#)

### Search History

DATE: Tuesday, April 25, 2006 [Printable Copy](#) [Create Case](#)

**Set**  
**Name**  
side by

**Query**

**Hit**  
**Count**

**Set**  
**Name**

Generate Collection

Print

**Search Results** - Record(s) 1 through 2 of 2 returned.

☐ 1. [20050048476](#). 06 Dec 01. 03 Mar 05. Novel chimeric TNF ligands. [Prussak, Charles E.](#), et al. 435/6; 435/320.1 435/325 435/69.5 530/351 536/23.5 C12Q001/68 C07H021/04 C12P021/02 C12N005/06 C07K014/52.

☐ 2. [WO2003050254A](#). New isolated polynucleotide sequence encoding a chimeric tumor necrosis factor (TNF)-alpha, useful for treating neoplasia, e.g. leukemia, gliomas, lymphomas or cancers of the breast, cervix, ovary, lung, bladder and prostate. [CANTWELL, M J](#), et al. A61K031/7088 A61K039/00 A61K048/00 A61P035/00 C07H021/04 C07K014/52 C07K014/525 C07K019/00 C12N000/00 C12N005/06 C12N005/10 C12N015/09 C12N015/12 C12N015/62 C12P021/02 C12P021/04 C12Q001/68.

Generate Collection

Print

Term	Documents
CHIMERIC	57358
CHIMERICS	376
CHIMAERIC	1980
CHIMAERICS	4
CD40L	2481
CD40LS	4
CD154	1119
CD154S	6
CD40	6168
CD40S	0
LIGAND	136472
((L1 OR L2 OR L3) AND (CHIMERIC OR CHIMAERIC)SAME (TNF\$)SAME(CD40L OR CD154 OR CD40 ADJ LIGAND OR 5C8 OR GP39)).PGPB,USPT,EPAB,JPAB,DWPI.	2

[There are more results than shown above. Click here to view the entire set.](#)

[Prev Page](#)[Next Page](#)[Go to Doc#](#)

First Hit

L4: Entry 1 of 2

File: PGPB

Mar 3, 2005

PGPUB-DOCUMENT-NUMBER: 20050048476  
PGPUB-FILING-TYPE: new  
DOCUMENT-IDENTIFIER: US 20050048476 A1

TITLE: Novel chimeric TNF ligands

PUBLICATION-DATE: March 3, 2005

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
<u>Prussak</u> , Charles E.	San Diego	CA	US
<u>Kipps</u> , Thomas J.	Rancho Santa Fe	CA	US
<u>Cantwell</u> , Mark J.	San Diego	CA	US

## ASSIGNEE-INFORMATION:

NAME	CITY	STATE	COUNTRY	TYPE	CODE
The Regents of the University of California					02

APPL-NO: 10/006305 [PALM]  
DATE FILED: December 6, 2001

INT-CL-PUBLISHED: [07] C12 Q 1/68, C07 H 21/04, C12 P 21/02, C12 N 5/06,  
C07 K 14/52

US-CL-PUBLISHED: 435/006; 435/069.5, 435/320.1, 435/325, 530/351, 536/023.5  
US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.5, 530/351, 536/23.5

REPRESENTATIVE-FIGURES: NONE

## ABSTRACT:

The present invention is directed to an isolated polynucleotide sequence encoding a chimeric TNF.alpha., comprising a first nucleotide sequence encoding a domain or subdomain of a tumor necrosis factor ligand other than TNF.alpha., wherein the encoded domain or subdomain replaces a cleavage site of native TNF.alpha., and a second nucleotide sequence encoding a domain or subdomain of native TNF.alpha. that binds to a TNF.alpha. receptor. The encoded chimeric TNF.alpha. is significantly less susceptible to cleavage from the cellular surface and, as a result can increase the concentration of a ligand capable of binding to a TNF.alpha. receptor on the surface of a cell. The chimeric TNF.alpha. is therefore useful in methods for inducing apoptosis of a cell expressing a TNF.alpha. receptor, inducing activation of an immune system cell and treating neoplastic cells, by introducing into the cell of interest an isolated polynucleotide sequence encoding a chimeric TNF.alpha. that is expressed on the surface of the cell.

First Hit

L4: Entry 1 of 2

File: PGPB

Mar 3, 2005

PGPUB-DOCUMENT-NUMBER: 20050048476  
PGPUB-FILING-TYPE: new  
DOCUMENT-IDENTIFIER: US 20050048476 A1

TITLE: Novel chimeric TNF ligands

PUBLICATION-DATE: March 3, 2005

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
<u>Prussak</u> , Charles E.	San Diego	CA	US
<u>Kipps</u> , Thomas J.	Rancho Santa Fe	CA	US
<u>Cantwell</u> , Mark J.	San Diego	CA	US

## ASSIGNEE-INFORMATION:

NAME	CITY	STATE	COUNTRY	TYPE	CODE
The Regents of the University of California					02

APPL-NO: 10/006305 [PALM]  
DATE FILED: December 6, 2001

INT-CL-PUBLISHED: [07] C12 Q 1/68, C07 H 21/04, C12 P 21/02, C12 N 5/06,  
C07 K 14/52

US-CL-PUBLISHED: 435/006; 435/069.5, 435/320.1, 435/325, 530/351, 536/023.5  
US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.5, 530/351, 536/23.5

REPRESENTATIVE-FIGURES: NONE

## ABSTRACT:

The present invention is directed to an isolated polynucleotide sequence encoding a chimeric TNF.alpha., comprising a first nucleotide sequence encoding a domain or subdomain of a tumor necrosis factor ligand other than TNF.alpha., wherein the encoded domain or subdomain replaces a cleavage site of native TNF.alpha., and a second nucleotide sequence encoding a domain or subdomain of native TNF.alpha. that binds to a TNF.alpha. receptor. The encoded chimeric TNF.alpha. is significantly less susceptible to cleavage from the cellular surface and, as a result can increase the concentration of a ligand capable of binding to a TNF.alpha. receptor on the surface of a cell. The chimeric TNF.alpha. is therefore useful in methods for inducing apoptosis of a cell expressing a TNF.alpha. receptor, inducing activation of an immune system cell and treating neoplastic cells, by introducing into the cell of interest an isolated polynucleotide sequence encoding a chimeric TNF.alpha. that is expressed on the surface of the cell.

Set	Items	Description
S1	23	E1-E4
S2	22	RD S1 (unique items)
S3	429	E1-E6
S4	83	S3 AND (CD40L OR CD40(W)LIGAND OR GP39 OR CD154 OR 5C8)
S5	63	RD S4 (unique items)
S6	20	S5 AND TNF?
S7	20	RD S6 (unique items)
S8	3	(CD40L OR CD40(W)LIGAND OR GP39 OR CD154 OR 5C8) (20N) (TNF?- ) (20N) (CHIMERIC OR CHIMAERIC)
S9	3	RD S8 (unique items)
S10	0	(CD40L OR CD40(W)LIGAND OR GP39 OR CD154 OR 5C8) (20N) (TNF?- ) (20N) (FUSION(W) PROETIN?)
S11	26	(CD40L OR CD40(W)LIGAND OR GP39 OR CD154 OR 5C8) (20N) (TNF?- ) (20N) (FUSION(W) PROTEIN?)
S12	17	RD S11 (unique items)
?		

ds

```
Set      Items  Description
S1        23    E1-E4
S2        22    RD S1  (unique items)
S3       429    E1-E6
S4        83    S3 AND (CD40L OR CD40(W)LIGAND OR GP39 OR CD154 OR 5C8)
S5        63    RD S4  (unique items)
S6        20    S5 AND TNF?
S7        20    RD S6  (unique items)
S8         3    (CD40L OR CD40(W)LIGAND OR GP39 OR CD154 OR 5C8) (20N) (TNF?-
) (20N) (CHIMERIC OR CHIMAERIC)
S9         3    RD S8  (unique items)
S10        0    (CD40L OR CD40(W)LIGAND OR GP39 OR CD154 OR 5C8) (20N) (TNF?-
) (20N) (FUSION(W) PROETIN?)
S11       26    (CD40L OR CD40(W)LIGAND OR GP39 OR CD154 OR 5C8) (20N) (TNF?-
) (20N) (FUSION(W) PROTEIN?)
S12       17    RD S11 (unique items)
? s (cd40L or cd40(w)ligand or gp39 or cd154 or 5c8) (20n) (tnf?) and (chimeric or
chimaeric) (10n) (ligand?r protein? conjugat?)
    6743    CD40L
    27276   CD40
    455163  LIGAND
    12843   CD40 (W) LIGAND
    694     GP39
    3097    CD154
    135     5C8
    214105  TNF?
    1204    (((CD40L OR CD40 (W) LIGAND) OR GP39) OR CD154) OR
    5C8) (20N) TNF?
    97017   CHIMERIC
    3430    CHIMAERIC
    0       LIGAND?R PROTEIN? CONJUGAT?
    0       (CHIMERIC OR CHIMAERIC) (10N) LIGAND?R PROTEIN? CONJUGAT?
S13        0    (CD40L OR CD40 (W) LIGAND OR GP39 OR CD154 OR
    5C8) (20N) (TNF?) AND (CHIMERIC OR CHIMAERIC) (10N) (LIGAND?R
    PROTEIN? CONJUGAT?)
? s (cd40L or cd40(w)ligand or gp39 or cd154 or 5c8) (20n) (tnf?) and (chimeric or
chimaeric) (10n) (ligand? or protein? or conjugat?)
Processing
    6743    CD40L
    27276   CD40
    455163  LIGAND
    12843   CD40 (W) LIGAND
    694     GP39
    3097    CD154
    135     5C8
    214105  TNF?
    1204    (((CD40L OR CD40 (W) LIGAND) OR GP39) OR CD154) OR
    5C8) (20N) TNF?
    97017   CHIMERIC
    3430    CHIMAERIC
    605586  LIGAND?
    7080631 PROTEIN?
    352062  CONJUGAT?
    41839   (CHIMERIC OR CHIMAERIC) (10N) ((LIGAND? OR PROTEIN?) OR
    CONJUGAT?)
S14       13    (CD40L OR CD40 (W) LIGAND OR GP39 OR CD154 OR
    5C8) (20N) (TNF?) AND (CHIMERIC OR CHIMAERIC) (10N) (LIGAND?
    OR PROTEIN? OR CONJUGAT?)
? rd s14
S15       12    RD S14  (unique items)
? t s15.3.akk'
>>>Warning: unmatched quote found
>>>'S15.3.AKK' not recognized as set or accession number
? t s15/3/all
```

Set	Items	Description
S1	23	E1-E4
S2	22	RD S1 (unique items)
S3	429	E1-E6
S4	83	S3 AND (CD40L OR CD40(W)LIGAND OR GP39 OR CD154 OR 5C8)
S5	63	RD S4 (unique items)
S6	20	S5 AND TNF?
S7	20	RD S6 (unique items)
S8	3	(CD40L OR CD40(W)LIGAND OR GP39 OR CD154 OR 5C8) (20N) (TNF?-(20N) (CHIMERIC OR CHIMAERIC)
S9	3	RD S8 (unique items)
S10	0	(CD40L OR CD40(W)LIGAND OR GP39 OR CD154 OR 5C8) (20N) (TNF?-(20N) (FUSION(W) PROETIN?)
S11	26	(CD40L OR CD40(W)LIGAND OR GP39 OR CD154 OR 5C8) (20N) (TNF?-(20N) (FUSION(W) PROTEIN?)
S12	17	RD S11 (unique items)
? s		(cd40L or cd40(w)ligand or gp39 or cd154 or 5c8) (20n) (tnf?) and (chimeric or chimaeric) (10n) (ligand?r protein? conjugat?)
	6743	CD40L
	27276	CD40
	455163	LIGAND
	12843	CD40 (W) LIGAND
	694	GP39
	3097	CD154
	135	5C8
	214105	TNF?
	1204	((((CD40L OR CD40 (W) LIGAND) OR GP39) OR CD154) OR 5C8) (20N) TNF?
	97017	CHIMERIC
	3430	CHIMAERIC
	0	LIGAND?R PROTEIN? CONJUGAT?
	0	(CHIMERIC OR CHIMAERIC) (10N) LIGAND?R PROTEIN? CONJUGAT?
S13	0	(CD40L OR CD40 (W) LIGAND OR GP39 OR CD154 OR 5C8) (20N) (TNF?) AND (CHIMERIC OR CHIMAERIC) (10N) (LIGAND?R PROTEIN? CONJUGAT?)
? s		(cd40L or cd40(w)ligand or gp39 or cd154 or 5c8) (20n) (tnf?) and (chimeric or chimaeric) (10n) (ligand? or protein? or conjugat?)
Processing		
	6743	CD40L
	27276	CD40
	455163	LIGAND
	12843	CD40 (W) LIGAND
	694	GP39
	3097	CD154
	135	5C8
	214105	TNF?
	1204	((((CD40L OR CD40 (W) LIGAND) OR GP39) OR CD154) OR 5C8) (20N) TNF?
	97017	CHIMERIC
	3430	CHIMAERIC
	605586	LIGAND?
	7080631	PROTEIN?
	352062	CONJUGAT?
	41839	(CHIMERIC OR CHIMAERIC) (10N) ((LIGAND? OR PROTEIN?) OR CONJUGAT?)
S14	13	(CD40L OR CD40 (W) LIGAND OR GP39 OR CD154 OR 5C8) (20N) (TNF?) AND (CHIMERIC OR CHIMAERIC) (10N) (LIGAND? OR PROTEIN? OR CONJUGAT?)
? rd s14		
S15	12	RD S14 (unique items)
? t s15.3.akk'		
>>>Warning: unmatched quote found		
>>>'S15.3.AKK' not recognized as set or accession number		
? t s15/3/all		



Gambel, Phillip

---

Subject: 10 /006,305 prussak

stic

**please provide the following references to**

**phillip gambel**

**art unit 1644**

**272-0844**

**1644 mailbox 3c70**

((9

2/3/8 (Item 8 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2006 BIOSIS. All rts. reserv.

0013563975 BIOSIS NO.: 200200157486  
Novel chimeric forms of human CD154 that can be expressed at high levels on  
the surface of CLL B cells  
AUTHOR: Hoo William Soo (Reprint); Allen John R (Reprint); Cantwell Mark J  
(Reprint); Li Mei (Reprint); Kipps Thomas J; Prussak Charles E  
(Reprint)

**AUTHOR ADDRESS: Tragen Pharmaceuticals, La Jolla, CA, USA\*\*USA**

**JOURNAL: Blood 98 (11 Part 2): p407b November 16, 2001 2001**

MEDIUM: print

CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of  
Hematology, Part 2 Orlando, Florida, USA December 07-11, 2001; 20011207

SPONSOR: American Society of Hematology

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

\*\*\*\*\*8888

2/3/7 (Item 7 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2006 BIOSIS. All rts. reserv.

0013593405 BIOSIS NO.: 200200186916  
Membrane-stabilized chimeric tumor necrosis factor for gene therapy of B  
cell malignancies  
AUTHOR: Cantwell Mark J (Reprint); Li Mei (Reprint); Prussak Charles  
(Reprint); Kipps Thomas J

**AUTHOR ADDRESS: Tragen Pharmaceuticals, La Jolla, CA, USA\*\*USA**

**JOURNAL: Blood 98 (11 Part 1): p423a November 16, 2001 2001**

**MEDIUM: print**

CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of

Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001; 20011207  
SPONSOR: American Society of Hematology  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Abstract; Meeting Poster  
RECORD TYPE: Abstract  
LANGUAGE: English

\*\*\*\*\*

2/3/2 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2006 BIOSIS. All rts. reserv.

0014814489 BIOSIS NO.: 200400182175  
Novel chimeric tumor necrosis factor-alpha has enhanced membrane stability  
and anti-tumor biologic activity.  
AUTHOR: Cantwell Mark J (Reprint); Rieger Roman; Prussak Charles  
(Reprint); Kipps Thomas J  
AUTHOR ADDRESS: Tragen Pharmaceuticals, San Diego, CA, USA\*\*USA  
JOURNAL: **Blood 102 (11): p500b November 16, 2003 2003**

**MEDIUM: print**

CONFERENCE/MEETING: 45th Annual Meeting of the American Society of  
Hematology San Diego, CA, USA December 06-09, 2003; 20031206  
SPONSOR: American Society of Hematology  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Abstract  
RECORD TYPE: Abstract  
LANGUAGE: English

\*\*\*\*\*

7/3/11 (Item 11 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2006 BIOSIS. All rts. reserv.

0013557943 BIOSIS NO.: 200200151454  
Biochemical studies on the TNF family members CD154, FasL, and  
LIGHT using the Semliki Forest virus vector system  
AUTHOR: Gutjahr Thorsten S (Reprint); Aviguetero Margaux A (Reprint);  
Kipps Thomas J (Reprint)  
AUTHOR ADDRESS: Department of Medicine, Division of Hematology/Oncology,  
University of California, San Diego, La Jolla, CA, USA\*\*USA  
JOURNAL: **Blood 98 (11 Part 2): p35b November 16, 2001 2001**

**MEDIUM: print**

CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of  
Hematology, Part 2 Orlando, Florida, USA December 07-11, 2001; 20011207  
SPONSOR: American Society of Hematology  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Abstract  
RECORD TYPE: Abstract

\*\*\*\*\*8

7/7/12 (Item 12 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2006 BIOSIS. All rts. reserv.

0013117290 BIOSIS NO.: 200100289129  
TRAF-family protein expression in normal tissues and lymphoid malignancies

AUTHOR: Zapata Juan M (Reprint); Krajewska Maryla (Reprint); Krajewski Stanislaw (Reprint); Kitada Shinichi (Reprint); Welsh Kate (Reprint); Monks Anne; McCloskey Natalie; Gordon John; Kipps Thomas; Gascoyne Randy D; Shabaik Ahmed; Reed John C (Reprint)

AUTHOR ADDRESS: The Burnham Institute, La Jolla, CA, USA\*\*USA

JOURNAL: **Blood 96 (11 Part 2): p143b November 16, 2000 2000**

MEDIUM: print

CONFERENCE/MEETING: 42nd Annual Meeting of the American Society of Hematology San Francisco, California, USA December 01-05, 2000; 20001201

SPONSOR: American Society of Hematology

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

**ABSTRACT:** The TRAFs constitute a family of signal transducing adapter proteins which associate with cytokine receptors, particularly the Tumor Necrosis Factor Receptor (TNFR)-family. Humans and mice contain six TRAF genes, but little information is available concerning which cell-types express these signal-transducing molecules in normal or neoplastic tissues. The in vivo locations of TRAF1, TRAF2, TRAF5, and TRAF6 were determined in human and mouse tissues by immunohistochemical methods. Striking diversity was observed in the patterns of immunostaining obtained for each of these TRAF-family proteins, suggesting that they are independently regulated and implying unique cell type-specific roles for certain TRAF-family proteins in cytokine signal transduction. Dynamic regulation of TRAFs was observed in cultured peripheral blood lymphocytes, where anti-CD3 antibodies, mitogenic lectins, and interleukins induced marked increases in the steady-state levels of TRAF1, TRAF2, TRAF5 and TRAF6. TRAF1 was also highly inducible by CD40-Ligand in cultured germinal center B-cells, whereas TRAF2, TRAF3, TRAF5, and TRAF6 were relatively unchanged. Analysis of 83 established human tumor cell lines by semi-quantitative immunoblotting methods revealed a tendency of certain types of malignant cell lines to express particular TRAFs but not others. Expression of TRAF1, for example, was highly restricted, with B-cell lymphomas most consistently expressing this TRAF-family member. Consistent with results from tumor cell lines, immunohistochemical analysis of 232 non-Hodgkin lymphoma (NHLs) revealed over-expression of TRAF1 in 112 cases (48%). TRAF1 protein levels were also elevated in circulating B-cell chronic lymphocytic leukemia (B-CLL) specimens (n=49), compared to normal peripheral blood B-cells, as determined by immunoblotting. Taken together, these findings contribute to an improved understanding of the tissue-specific roles of TRAFs in normal tissues and provide evidence of altered TRAF1 expression in lymphoid malignancies.

\*\*\*\*\*

12/3/4 (Item 4 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 BIOSIS. All rts. reserv.

0012867962 BIOSIS NO.: 200100039801

CD40L (CD154) fusion protein with pulmonary surfactant protein D as a prototype for soluble multimeric TNF superfamily ligand molecules

AUTHOR: Kornbluth R S (Reprint); Kee K (Reprint); Truong N H (Reprint)

AUTHOR ADDRESS: University of California San Diego and VA San Diego Healthcare System, La Jolla, CA, USA\*\*USA

JOURNAL: **FASEB Journal 14 (6): pA1162 April 20, 2000 2000**

MEDIUM: print

CONFERENCE/MEETING: Joint Annual Meeting of the American Association of Immunologists and the Clinical Immunology Society Seattle, Washington, USA

May 12-16, 2000; 20000512

ISSN: 0892-6638

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Citation

LANGUAGE: English